Bio‑Techne Corporation, a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in ...

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The combined solutions support characterization capabilities for antibodies that cannot be achieved using standalone methods.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

MINNEAPOLIS, Nov. 15, 2022 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The ...

Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market. This partnership allows ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

With a new name and a new CEO, Bio-Techne has begun an aggressive growth strategy to ensure that researchers know not only its flagship brand, R&D Systems, but the company as a whole. One year ago, ...